Case Report Location of a Dexamethasone Implant at the...

Case ReportLocation of a Dexamethasone Implant at the Macula afterIntravitreal Injection in a Silicone Oil-Filled Eye

Cenap Mahmut Esenulku1 and Murat Gunay2

1Department of Ophthalmology, Trabzon Kanuni Training and Research Hospital, Trabzon, Turkey2Department of Ophthalmology, Trabzon Fatih State Hospital, Trabzon, Turkey

Correspondence should be addressed to Murat Gunay; drmurat301@yahoo.com.tr

Received 4 July 2016; Accepted 7 November 2016

Academic Editor: Motohiro Kamei

Copyright © 2016 C. M. Esenulku and M. Gunay. This is an open access article distributed under the Creative CommonsAttribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work isproperly cited.

Here, we report a case with cystoid macular edema (CME) due to central retinal vein occlusion (CRVO) presented with adexamethasone implant (Ozurdex) trapped at the macula in her silicone oil- (SO-) filled eye after injection. No additionalcomplications such as intraocular pressure (IOP) rise or retinal damage were observed.TheCMEwas resolved during the follow-upperiod. At the last visit, 3 months following the injection, Ozurdex implant was found to bemostly dissolved without any additionalocular complications.

1. Introduction

Macular edema (ME) is the most common cause fordecreased visual performance in patients with retinal veinocclusion (RVO). Elevated levels of vascular endothelialgrowth factor (VEGF) and breakdown of the blood-retinalbarrier with subsequent release of inflammatory mediatorscontribute to the development of ME in RVO [1]. Apart fromthe intravitreal anti-VEGF therapy, Ozurdex (dexamethasone0.7mg) has been approved in the form of an intravitrealimplant for the treatment of ME associated with RVOs [2].

Afshar et al. [3] firstly described a case with Ozurdeximplant on the macula after surgical repair for recurrentretinal detachment with silicone oil (SO) administration. Inthat report, the implant remained trapped between siliconeoil and retinal surface and thenmoved away from themacularemaining as a pigmented epiretinal membrane. Studies thenshowed several abnormalities related to intravitreal dexam-ethasone implant in SO-filled eyes [4–6]. In the presentreport, we aimed to demonstrate the clinical course of acase with ME due to central RVO (CRVO) presenting withOzurdex implant on the macula in a SO-filled eye.

2. Case Report

A 55-year-old woman with a history of CRVO presentedwith reduced visual acuity (VA) in her left eye that persistsfor one month. In the first visit, her best corrected visualacuity (BCVA) was 20/20 in the right eye and 10/200 inthe left eye. She has no systemic abnormality except forhypertension. No abnormality in the anterior segment exam-ination of both eyes was observed. The intraocular pressure(IOP) measurements were 13mmHg in both eyes. Fundusexamination revealed CRVO related findings. On spectraldomain optical coherence tomography (SD-OCT, SpectralisHRA+OCT, Heidelberg Engineering, Heidelberg, Germany)analysis, cystoid ME (CME) was detected in the left eye.Fundus Fluorescein Angiography (FFA) examination wascompatible with CRVO. The patient had already received7 doses of intravitreal ranibizumab, 3 doses of intravit-real aflibercept, and an intravitreal dexamethasone implant(Ozurdex, Allergan Inc., Irvine, CA) at our center.

After eleven months of the first visit, the patient hadundergone a combined procedure of phacoemulsificationand pars plana vitrectomy (PPV)with SO injection at another

Hindawi Publishing CorporationCase Reports in Ophthalmological MedicineVolume 2016, Article ID 5107652, 3 pageshttp://dx.doi.org/10.1155/2016/5107652

2 Case Reports in Ophthalmological Medicine

Figure 1: Optical coherence tomography analysis shows hyper-reflectance of the intravitreal dexamethasone implant at the foveawith optical shadowing.

center for persisting CME. Patient was admitted to ourhospital with visual complaints in the left eye one weekafter the surgery. The BCVAs were 20/20 and 5/200 inthe right and left eyes, respectively. CME was still presenton OCT examination. Intravitreal Ozurdex injection wasconsidered. On postinjection first day, the patient complainsabout a central linear scotoma in her left eye. On fundusexamination, the implant was detected at the macula on thefovea (Figure 1). Clinical observation was considered. Theimplant gradually dissolved during 3 months. No recurrencein CME was detected during the follow-up. No additionalcomplication was noted. The intravitreal implant was foundto be mostly dissolved 3 months following the injection andno CME was detected. Central linear scotoma was relievedafter dissolution of the implant.

3. Discussion

It was stated that intravitreal injection of an implant maynot be suitable in a SO-filled eye. Several concerns on thisissue have been proposed including a possible increase inIOP due to volume expansion, improper dissolution of thedrug in SO, and prevention of the diffusion of the drug tomacula [7]. Kim et al. [5] implanted Ozurdex intravitreallyafter vitrectomy for a chronic uveitis case in a SO-filled eye.They suggested the use of intravitreal dexamethasone implantin SO-filled vitrectomized eyes in refractory ME secondaryto chronic uveitis.We observed successful regression of CMEafterOzurdex in the present case. Regression of CME in a SO-filled eye in our case has shown a benefit for patients treatedwith intravitreal Ozurdex.

Wai Ch’Ng et al. [8] reported the displacement of anintravitreal Ozurdex implant to the anterior vitreus cavity 2weeks after the implantation.The authors attributed this com-plication to the slow migration of the implant to the hyaloidfossa due to the absence of posterior vitreous detachment inthe patient. Banerjee et al. [6] reported a similar case in apseudophakic SO-filled eye in which the implant was trappedbetween the posterior capsule and anterior of the SO bubble.They suggested the SO’s buoyancy force as a contributingfactor to the implant position in a vitrectomized SO-filled eye.

In both cases, no further adverse events were noted. In ourcase, the implant was detected on the macula one day afterthe injection similar to the case reported by Afshar et al. [3].However, we did not observe an ERM formation at location ofthe implant as seen in that study.The possible explanation forthe trapping of an intravitreal implant at the macula in a SO-filled eye was suggested to be the static environment betweenthe SO and fluid space on the retinal surface; thus, the implantmay be immobilized at the same position during a period oftime [3].This was 1 month for the previous case and 3monthsfor our case.

In an experimental study, it has been shown that velocityof the dexamethasone implant is slower in vitreous thanin water and that decreases exponentially over distance invitreous [9]. Differences in velocity might be related to theviscosity of media filled in the eye. The velocity of thedexamethasone implant might be lower in SO-filled eye dueto high viscosity of SO.

In conclusion, the presence of the intravitreal dexam-ethasone implant at the macula in a SO-filled eye afterthe injection might be a common complication. Physiciansshould keep inmind this possible phenomenonwhile admin-istering intravitreal dexamethasone implant in a SO-filledeye. In our opinion, further studies are needed in order tobetter understand the underlying mechanism of this kind ofcomplication.

Competing Interests

The authors declare that they have no competing interests.

References

[1] Baseline and Early Natural History Report, “The central veinocclusion study,” Archives of Ophthalmology, vol. 111, no. 8, pp.1087–1095, 1993.

[2] S. J. Ryder, D. Iannetta, S. D. Bhaleeya, and S. Kiss, “Efficacy andtolerability of bilateral sustained-release dexamethasone intrav-itreal implants for the treatment of noninfectious posterioruveitis andmacular edema secondary to retinal vein occlusion,”Clinical Ophthalmology, vol. 9, pp. 1109–1116, 2015.

[3] A. R. Afshar, A. R. Loh, P. Pongsachareonnont, D. M. Schwartz,and J.M. Stewart, “Dexamethasone intravitreal implant trappedat the macula in a silicone oil-filled eye,” Ophthalmology, vol.120, no. 12, pp. 2748–2749, 2013.

[4] S. J. Bakri and S. T. Alniemi, “Fibrotic encapsulation of adexamethasone intravitreal implant following vitrectomy andsilicone oil for rhegmatogenous retinal detachment,” Oph-thalmic Surgery Lasers and Imaging Retina, vol. 45, no. 3, pp.243–245, 2014.

[5] J. T. Kim, Y. H. Yoon, D. H. Lee, S. G. Joe, and J.-G. Kim, “Dex-amethasone intravitreal implant in the silicone oil-filled eye forthe treatment for recurrent macular oedema associated withankylosing spondylitis: a case report,” Acta Ophthalmologica,vol. 91, no. 4, pp. e331–e332, 2013.

[6] P. J. Banerjee, P. Petrou, T. M. Zvobgo, and D. G. Charteris,“Spontaneous relocation of a trapped retrolenticular slow-release dexamethasone implant (Ozurdex) in a silicone oil-filledeye of a pseudophakic patient,” Eye, vol. 28, no. 8, pp. 1036–1037,2014.

Case Reports in Ophthalmological Medicine 3

[7] M. S. Spitzer, R. T. Kaczmarek, E. Yoeruek et al., “The distri-bution, release kinetics, and biocompatibility of triamcinoloneinjected and dispersed in silicone oil,” Investigative Ophthalmol-ogy & Visual Science, vol. 50, no. 5, pp. 2337–2343, 2009.

[8] S. Wai Ch’Ng, S. Padroni, and S. Banerjee, “Anterior vitreousdisplacement of the intravitreal dexamethasone implant (Ozur-dex),” Eye, vol. 28, no. 2, pp. 238–239, 2014.

[9] C. H. Meyer, A. Klein, F. Alten et al., “Release and velocity ofmicronized dexamethasone implants with an intravitreal drugdelivery system: kinematic analysis with a high-speed camera,”Retina, vol. 32, no. 10, pp. 2133–2140, 2012.

Submit your manuscripts athttp://www.hindawi.com

Stem CellsInternational

Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

MEDIATORSINFLAMMATION

Behavioural Neurology

EndocrinologyInternational Journal of

Disease Markers

BioMed Research International

OncologyJournal of

Oxidative Medicine and Cellular Longevity

PPAR Research

The Scientific World JournalHindawi Publishing Corporation http://www.hindawi.com Volume 2014

Immunology ResearchHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014

Journal of

ObesityJournal of

Computational and Mathematical Methods in Medicine

OphthalmologyJournal of

Diabetes ResearchJournal of

Research and TreatmentAIDS

Gastroenterology Research and Practice

Parkinson’s Disease

Evidence-Based Complementary and Alternative Medicine

Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com

Case Report Location of a Dexamethasone Implant at the...

Documents

Transcript of Case Report Location of a Dexamethasone Implant at the...

Dexamethasone PL 17507-0053 - GOV.UK · PDF filePL 17507/0053 UKPAR Auden Mckenzie, Dexamethasone 2mg Tablets 1 Public Assessment Report Dexamethasone 2mg Tablets Dexamethasone PL

CBAS5539 Clinical performance of a new implant system for bone … · 2019. 12. 11. · • BI300 Implant length • Location of BI300 Implant • Surgical incision type/location

Signal Transduction Pathways in use of Dexamethasone Implant … · 2018-11-06 · Signal Transduction Pathways in use of Dexamethasone Implant in the Eye. Yakup Cevik. 1, Bekir Kucuk.

Sustained Dexamethasone Drug Delivery System

OZURDEX DME Product Monograph (non-annotated) · 4/14/2015 · OZURDEX® (dexamethasone intravitreal implant 0.7 mg) is indicated for: the treatment of macular edema following central

Effect of intravitreal ,YJCho , CH Lee and SC Lee · 2019-09-04 · Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular

Effect of implant- and occlusal load location on stress distribution … · 2017-10-16 · The Journal of Advanced Prosthodontics 371 Effect of implant- and occlusal load location

Dexamethasone Intravitreal Implant in Diabetic Macular ...

Public Assessment Report UK PAR Dexamethasone 4 … · Public Assessment Report UK PAR Dexamethasone 4 mg Tablets Dexamethasone 8 mg Tablets PL 00289/2198-2199 Teva UK Limited

Ozurdex, INN- Dexamethasone · Ozurdex contains an extruded dosage form of 700 µg dexamethasone (DEX), in an inactive biodegradable polymer matrix , also referred to as dexamethasone

InjectIon technIques - Retina Todayretinatoday.com/pdfs/0613_insert.pdf · InjectIon technIques for OZURDEX® (Dexamethasone Intravitreal Implant) 0.7 mg Covered topics include: Profiles

Dexamethasone Sodium Phosphate DOSAGE AND ...editor.fresenius-kabi.us/PIs/US-PH-Simplist...Dexamethasone Sodium Phosphate Injection, USP, is a water-soluble inorganic ester of dexamethasone

PRODUCT MONOGRAPH Including Patient Medication Information · OZURDEX® (dexamethasone intravitreal implant 0.7 mg) is indicated for: • the treatment of macular edema following

Acute Onset of Exogenous Endophthalmitis after ...CaseReport Acute Onset of Exogenous Endophthalmitis after Dexamethasone Implant Injection Treated without Implant Removal GeorgeG.Bastakis

Ozurdex (dexamethasone intravitreal implant) · drug-delivery system (DDS) a drug delivery system, is surgically implanted in the vitreous of the eye for sustained release ... Selection

Implants and Additives Galen Erickson. Implanting Defects Partially missing implant Improper Location Crushed Implants.

Use of Dexamethasone Intravitreal Implant for the treatment of … · 2017-10-10 · The inflammation magnitude in the ME progressively increases as long as time went by. For the

Expert Insights in Today’s Multidisciplinary Management of … · 2015-09-22 · choose the dexamethasone implant first because the safety profile is more desirable than that for

Subconjunctival Dexamethasone Implant

Dexamethasone Intravitreal Implant as Adjunctive Therapy ...